LMLena M. Mattes

Lena M. Mattes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lena M. Mattes has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Bernhard G. Weiss

    Department for Otorhinolaryngology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany

    1 shared publication
  • Frank Haubner

    Department of Otorhinolaryngology University Hospital, LMU Munich Munich Germany

    1 shared publication
  • Friedrich Ihler

    Department of Otorhinolaryngology University Hospital, LMU Munich Munich Germany

    1 shared publication
  • Jennifer Lee Spiegel

    Department of Otolaryngology Head and Neck Surgery Sunnybrook Health Sciences Centre, University of Toronto Toronto Ontario Canada

    1 shared publication
  • Julia Hess

    Research Unit Radiation Cytogenetics, Helmholtz Zentrum München Research Center for Environmental Health (GmbH) Munich Germany

    1 shared publication
  • Julia Kitz

    Institute of Pathology University Medical Center Göttingen, Georg‐August‐Universität Göttingen Göttingen Germany

    1 shared publication

Latest Publications

  • Human microRNA ‐182‐5p and kinectin 1: Potential biomarkers for prognosis in oral squamous cell carcinoma

    by Mark Jakob, Lena M. Mattes, Kristian Unger, Stefan Kueffer, Julia Hess, Martin Canis, Markus Schirmer, Jennifer L. Spiegel, Frank Haubner, Friedrich Ihler, et al.

    Background The prognostic impact of hsa-miRNA-182-5p in oral cancer remains unexplored. Therefore, the aim of this study was to investigate the prognostic value of hsa-miRNA-182-5p and its predicted target kinectin 1 (KTN1) in oral squamous cell carcinoma (OSCC). Method Expression level of hsa-miRNA-182-5p was analyzed in tumor tissue (n = 36) and healthy oral mucosal tissue (n = 17) using quantitative real-time polymerase chain reaction. Protein level of the predicted target KTN1 was detected via immunohistochemistry. Results were validated in a cohort of The Cancer Genome Atlas (TCGA). Results After dividing the data into a subgroup with high and low hsa-miRNA-182-5p expression level, a significant better overall (p = 0.016), recurrence-free (p = 0.009), and progression-free survival (p = 0.004) was observed in an upregulation of hsa-miRNA-182-5p. Staining intensity of KTN1 showed a reciprocal impact on the prognosis. Validation in a TCGA cohort confirmed these results. Conclusion Our results indicate hsa-miRNA-182-5p and KTN1 as potential biomarkers for OSCC.